284462-78-8

Basic information

• Product Name: 4-(3-Aminophenoxy)-N-methylpicolinamide
• Synonyms: 2-Pyridinecarboxamide, 4-(3-aminophenoxy)-N-methyl-
• CAS NO: 284462-78-8
• Molecular Formula: C₁₃H₁₃N₃O₂
• Molecular Weight: 243.265
• Mol File: 284462-78-8.mol

Chemical Properties

• Boiling Point: 472.2 °C at 760 mmHg
• Flash Point: 239.4 °C
• Density: 1.241 g/cm³
• CAS DataBase Reference: 4-(3-Aminophenoxy)-N-methylpicolinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Aminophenoxy)-N-methylpicolinamide(284462-78-8)
• EPA Substance Registry System: 4-(3-Aminophenoxy)-N-methylpicolinamide(284462-78-8)

Safety Data

• Hazardous Substances Data: 284462-78-8(Hazardous Substances Data)

Upstream product

• 827029-02-7 C₁₃H₁₁N₃O₄ 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 591-27-5 m-Hydroxyaniline 
• 554-84-7 meta-nitrophenol 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 98-98-6 2-Picolinic acid 

Downstream Products

• 864272-28-6 C₁₃H₁₄N₄O₂ 
• 99586-65-9 4-chloropicolinamide 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 284462-92-6 3-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-4-methylaniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 1412891-41-8 4-(3-(3-(2,4-dichlorophenyl)thioureido)phenoxy)-N-methylpicolinamide 
• 1412891-42-9 4-(3-(3-(4-chlorophenyl)thioureido)phenoxy)-N-methylpicolinamide 
• 1412891-45-2 4-(3-(3-(3,4-difluorophenyl)thioureido)phenoxy)-N-methylpicolinamide 
• 1412891-49-6 N-methyl-4-(3-(3-(3-(trifluoromethyl)phenyl)thioureido)phenoxy)picolinamide 
• 1412891-55-4 4-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)thioureido)phenoxy)-N-methylpicolinamide 
• 1412891-60-1 N-methyl-4-(3-(3-(4-(trifluoromethoxy)phenyl)thioureido)phenoxy)picolinamide 
• 1400989-35-6 4-(3-(3-(trifluoromethoxy)benzylamino)phenoxy)-N-methylpyridine-2-carboxamide 
• 1400989-33-4 4-(3-(3-(trifluoromethyl)benzene-sulfonylamino)phenoxy)-N-methylpyridine-2-carboxamide 
• 1400989-34-5 4-(3-(benzene-carbonylamino)phenoxy)-N-methylpyridine-2-carboxamide 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Design, synthesis and biological activities of sorafenib derivatives as antitumor agents

A series of novel sorafenib derivatives, 9a-w, was designed and synthesized in high yields using various substituted anilines, and their antiproliferative activities against HCT116, PC-3 and MDA-MB-231 cell lines were also evaluated and described. All compounds exhibited potent antiproliferative activity against HCT116 and PC-3 cells with IC50 = 2.8-52.0 and 2.2-45.6 μM; compounds 9p and 9q demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines, the cytotoxicity of compound 9r is more potent than that of sorafenib. Compounds (9g, 9p, 9q and 9r) were chosen for further evaluation of the anti-angiogenesis activity, and showed the inhibition of sprout formation from aortic ring ex vivo. The structures of all the newly synthesized compounds were determined by 1H NMR, 13C NMR and HRMS.

NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.

PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS

Pyrimidine derivatives of formula (I), pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.

SEMICARBAZIDE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

MALONAMIDE DERIVATIVES

The present invention relates to malonamide derivatives of formula (I): A-D-B, the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS

Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G', and G" represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.